ALK and non-small cell lung carcinoma: Interestingly, a focused drug screening of 30 kinase inhibitors revealed that brigatinib, a TKI clinically used in NSCLC patients with alterations in the anaplastic lymphoma kinase (ALK) gene, had an inhibitory effect against cells expressing triple-mutant EGFR.